Abstract Purpose:Tumor-localized activation of immune cells by membrane-tethered anti-CD3 antibodies (CD3L) is under investigation to treat poorly immunogenic tumors. Here we sought to elucidate the mechanism of antitumor immunity elicited by CD3L. Experimental Design: CD3L and CD86 were expressed on poorly immunogenic B16 melanoma cells (B16/3L86 cells) and the effect of various lymphocytes, including CD4 + and CD8 + Tcells, natural killerT (NKT) cells, and regulatoryTcells, on antitumor activity was investigated.
Anti-CD3 antibody -based therapies have been widely investigated for the treatment of cancer. Systemic administration of anti-CD3 antibodies was found to produce antitumor activity in patients but polyclonal activation of T cells caused severe side effects due to widespread release of cytokines (1, 2) . More localized activation of T cells in tumors can be achieved by using bispecific antibodies in which an anti-CD3 antibody is linked or fused to an antibody against antigens expressed on cancer cells. Bispecific antibodies have shown good antitumor activity both in animal models (3) and in clinical trials (4, 5) . However, limited cytolytic activity, low potency, and side effects associated with systemic T-cell activation have hampered more widespread utilization of bispecific antibodies (6) . More recently, novel potent bispecific antibody constructs are showing impressive anticancer activity in clinical trials (7) , emphasizing the potential of tumor-located ligation of CD3 on tumor-infiltrating lymphocytes (TIL) for improved cancer management.
Activation of lymphocytes by membrane-tethered immunestimulatory antibodies expressed locally on cancer cells provides an alternative treatment that retains benefits of bispecific antibodies while minimizing the adverse effects associated with systemic antibody administration. In this strategy, antibodies with specificity for activation receptors present on lymphocytes are expressed on the surface of cancer cells by fusing the antibody to a transmembrane domain or glycosylphosphatidylinositol anchor (8) . We and others have shown that membrane-tethered antibodies with specificity for CD3 or the T-cell receptor can potently trigger activation of naBve T cells and significantly suppress tumor growth in mice (9 -12) . Likewise, tumor-located expression of a membranetethered antibody against CD137, which is expressed on T cells, monocytes, dendritic cells, and natural killer (NK) cells, caused extensive rejection of poorly immunogenic tumors in mice (13, 14) . Similarly, tumor cells engineered to express membranetethered anti-CD16 scFv induced NK cell cytotoxicity and phagocytosis of tumor cells by macrophages in mice (15) . Local expression of immune-stimulatory antibodies may facilitate more selective activation of TILs and minimize systemic activation of immune cells, which can lead to unwanted toxicity.
Tumor-infiltrating regulatory T cells (Treg) play a crucial role in tumor immune evasion and are an obstacle for successful tumor therapy (16) . Due to their immunoregulatory function, Tregs can induce antigen-specific and nonspecific inhibition of T-cell activity (17, 18) . Clinically, Tregs have been found to accumulate in tumors of patients with ovarian cancer, lung cancer, melanoma, pancreatic cancer, breast cancer, and cervical cancer (19 -23) . Agents that deplete or inhibit Treg function can reverse suppression and promote T-cell -mediated cytotoxicity (24 -26) . However, it is currently unknown how Tregs affect the antitumor activity of lymphocytes that are directly activated in tumors by membrane-tethered antibodies.
NK cells are a subset of lymphocytes that express CD16 and a variety of activating and inhibiting receptors on their surface (27) . A major role of NK cells is surveillance of cells, such as those infected with viruses, which display low levels of MHC class I molecules. NKT cells are a T-cell subset defined by the coexpression of a T-cell receptor and NK-cell markers. Most NKT cells express an invariant T-cell receptor a chain with reactivity for the glycosphingolipid a-galactosylceramide presented by the class I -like molecule CD1d (28) . A distinguishing feature of NKT cells is their rapid production of multiple cytokines within hours of their activation.
The goal of this study was to elucidate the mechanism of the antitumor immune responses generated by tumor-located expression of membrane-tethered anti-CD3 antibodies. We hypothesized that direct activation of TILs might produce strong antitumor activity to overcome low tumor immunogenicity and Treg-mediated suppression of tumor immune responses. To test this, we examined the immune response against B16 melanoma cells that were engineered to express a membrane-tethered anti-CD3 antibody as well as CD86 to provide costimulation to T cells (10) . B16 melanoma cells were studied because these poorly immunogenic tumors are infiltrated with Tregs (29) . We show that expression of membranetethered anti-CD3 antibodies on B16 cells induced strong NKT antitumor activity and T-cell -mediated protection against subsequent challenge with unmodified B16 cancer cells, whereas direct T-cell antitumor activity was greatly enhanced by systemic Treg depletion.
Materials and Methods
Mice and cell lines. Female C57BL/6, BALB/c, and CD8-deficient (CD8a -/-, C57BL/6 background) mice were maintained in the Animal Center in the Institute of Biomedical Sciences (Taipei, Taiwan) under specific pathogen-free conditions. CD1d-deficient (CD1d -/-) mice were kindly provided by Dr. C. Wang (University of Chicago, Chicago, IL). Beige/severe combined immunodeficient mice were from the National Taiwan University (Taipei, Taiwan). All experiments were conducted in accordance with institutional guidelines for animal care and use.
B16F1 melanoma cells (B16 cells) were acquired from American Type Culture Collection. B16/3L, B16/Ox, B16/3L86, and B16/Ox86 cells denote B16 cells that expressed CD3L (membrane-tethered anti-CD3 scFv), membrane-anchored anti-phOx scFv (control scFv), CD3L and CD86, or anti-phOx scFv and CD86, respectively (9) . To generate B16/3L and B16/Ox cells, B16 cells were transfected with pLNCX-based vectors (Clontech) encoding anti-CD3 or anti-phOx scFv and selected in medium containing 1.2 mg/mL G418. B16/3L86 and B16/Ox86 cells were generated by cotransfecting B16 cells with pcDNA3.1/zeo -based vectors (Invitrogen) encoding murine CD86 and pLNCX-based vectors encoding anti-CD3 or anti-phOx scFv genes and selecting in medium containing 1.2 mg/mL G418 and 0.4 mg/mL zeocin. BALB/c 3T3 fibroblasts were obtained from National Health Research Institutes (Hsin Chu, Taiwan). 3T3/3L86 cells were generated by transfecting 3T3 cells with vectors encoding CD3L and CD86 and selecting in medium containing 1.2 mg/mL G418 and 0.4 mg/mL zeocin. TSA murine breast adenocarcinoma cells were kindly provided by Dr. P. Lollini (University of Bologna, Bologna, Italy). Cells were cultured in DMEM supplemented with 10% bovine serum and 1.2 mg/mL G418 alone or with 0.4 mg/mL zeocin at 37jC in an atmosphere of 5% CO 2 .
In vivo tumor growth. Groups of five to seven C57BL/6 mice were s.c. injected with 2 Â 10 6 wild-type (wt) or transfected B16 cells on their left flank (unless otherwise specified). Tumor dimensions were estimated as 0.5 Â height Â width Â length. Mice were sacrificed when tumor size exceeded 2,000 mm 3 . Mice that did not develop tumors within 60 d of initial tumor inoculation were rechallenged with 1 Â 10 5 B16 cells. For the experimental lung metastasis model, 10 5 wt or transfected B16 cells were i.v. injected via the tail vein of C57BL/6 mice. Mice were sacrificed 20 d after tumor inoculation to count lung tumor colonies under a dissecting microscope. Wt or transfected B16 tumor cells (10 6 ) were i.p. injected in groups of C57BL/6 mice to establish an i.p. tumor model. Mice that showed signs of illness or fatigue were killed. For assessing bystander killing effects, 2 Â 10 6 B16 melanoma cells were mixed with B16/3L86 tumor cells or 3T3/3L86 cells at a ratio of 1:1 and then injected s.c. into C57BL/6 mice. Likewise, 5 Â 10 5 TSA adenocarcinoma cells were mixed with an equal number of 3T3/3L86 cells before s.c. injection in BALB/c mice. Tumor growth was monitored for 60 d.
T-cell enrichment. Splenocytes isolated from C57BL/6 mice were treated with ACK buffer (0.15 mol/L NH 4 Cl, 10 mmol/L KHCO 3 , 0.1 mmol/L Na 2 EDTA, pH 7.2) to lyse RBC and then allowed to attach to culture plates for 2 h. Cells remaining in suspension were transferred to
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culture plates coated with 100 Ag of goat anti-mouse IgM, IgG, and IgA antibodies for 45 min at 37jC. Nonadherent cells were labeled with CD8a (Ly-2) microbeads and collected in an MS cell separation column according to the manufacturer's instructions (Miltenyi Biotech). Unbound cells were labeled with CD4 (L3T4) microbeads and purified in a similar fashion. The purity of enriched CD8 + and CD4 + T cells was 90% to 98% as determined by fluorescence-activated cell sorting (FACS).
Isolation of peritoneal mononuclear cells. Peritoneal exudate cells were retrieved by peritoneal lavage with 7 mL of DMEM supplemented with 10% bovine serum per mouse. The exudate cells were centrifuged and resuspended in 3 mL DMEM supplemented with 10% bovine serum. The cell suspension was then layered on top of 3 mL of FicollHistopaque 1083 (Sigma-Aldrich) and centrifuged at 400 Â g for 30 min. The opaque layer at the interface was recovered in PBS for further experiments.
Cytotoxicity assay. B16 or B16/3L86 tumor cells (10 6 ) were labeled with 0. FACS analysis and antibodies. Cells were blocked in FACS staining buffer (PBS containing 0.1% bovine serum albumin and 0.01% sodium azide) for 40 min at 4jC with 2 Ag/mL anti-FcgRII/III antibody (clone 2.4G2, BD Pharmingen), then labeled for 40 min with the appropriate specific antibodies followed by staining with propidium iodine at 5 Ag/mL. For intracellular staining of FoxP3 and IFN-g, cells were fixed with 4% paraformaldehyde and permeabilized with 0.1% saponin and 5% bovine serum albumin in PBS. The following antibodies were used: biotin-rat anti-mouse CD86 (clone GL1), biotin-hamster anti-mouse CD80 (clone 16-10A1), FITC-hamster anti-mouse CD3q (clone 145-2C11), phycoerythrin (PE)-rat anti-mouse CD4 (clone L3T4), PE-rat anti-mouse CD8 (clone Ly-2), PE-mouse anti-mouse NK1.1 (clone PK136), PE-rat IgG1 (clone R3-34), allophycocyanin-hamster antimouse CD3q (clone 145-2C11, all BD Pharmingen), Alexa Fluor 488-rat anti-mouse CD8 (clone 53-6.7, Biolegend), PE-rat anti-mouse IFN-g (clone XMG1.2, Biolegend), rat anti-hemagglutinin (HA; clone 3F10, Roche), FITC-goat anti-rat IgG(H+L) (Jackson ImmuoResearch), PE-rat anti-mouse Rae-1 (clone 186107, R&D Systems), rat anti-mouse MULT-1 (clone 237104, R&D Systems), PE-rat anti-mouse H60 (clone 205326, R&D Systems), FITC-rat anti-mouse CD1d (clone 1B1, eBioscience), and Alexa Fluor 647-rat anti-mouse/rat FoxP3 (clone FJK/-16S, eBioscience). The stained cells were then analyzed on a FACSCanto using FACSDiva software (both BD Biosciences). Only viable cells, determined on the basis of their forward scatter/side scatter and propidium iodine staining (propidium iodine -positive cells were excluded), were used in the analyses.
In vivo depletion of CD4 Adenovirus-mediated therapy. pJM17 harboring the adenovirus genome and pAd-cytomegalovirus shuttle vector were kindly provided by Dr. S.K. Shyue (Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan). cDNAs for membrane-tethered scFv and CD86 were cloned into pAd-cytomegalovirus and then cotransfected with pJM17 in 293N cells to produce recombinant adenovirus expressing CD3L (Ad/ 3L), CD86 (Ad/86), anti-phOx scFv (Ad/Ox), or anti-CD28 scFv (Ad/ 28L). BALB/c mice were s.c. inoculated with 5 Â 10 5 TSA tumor cells on day 0. On days 11 and 12, 10 9 plaque-forming units of Ad/3L were mixed with or without 10 9 plaque-forming units of Ad/86 or Ad/28L and directly injected into established TSA tumors in mice. As control groups, 10 9 plaque-forming units of Ad/Ox were also mixed with 10 9 plaque-forming units of Ad/86 or Ad/28L before intratumoral injection. Tumor growth was followed for 60 d. Statistics. Data of s.c. tumor growth, T-cell -mediated cytotoxicity, and lung metastasis were analyzed using two-way ANOVA. T-cell proliferation and peritoneal cell phenotyping were analyzed by twosided Student's t test. Animal survival was analyzed by the two-sided log-rank test. All analyses were done with GraphPad Prism 4 software. P V 0.05 was considered statistically significant.
Results
In vivo antitumor activity of membrane-tethered CD3L and CD86. Transgenes encoding membrane-anchored anti-CD3 . 1A and B) were transfected individually or with the CD86 costimulatory molecule to obtain stable B16 melanoma cell lines expressing CD3L (B16/3L), Ox (B16/Ox), or these membrane-tethered antibodies along with CD86 (B16/3L86 and B16/Ox86, respectively; Fig. 1C ). The phOx scFv specifically recognizes the chemical hapten 4-ethoxy-methylene-2-phenyl-2-oxazolin-5-one (30) . This scFv does not bind lymphocytes and was used as a negative control membrane-anchored antibody. Figure 1C also shows that none of the cells expressed endogenous CD80 and only those cells transfected with the CD86 expression vector (B16/3L86 and B16/Ox86) expressed CD86. The in vitro growth rates of B16, B16/3L, and B16/Ox cells were similar with doubling times of 14 to 15 hours (Supplementary Fig. S1 ). B16/3L86 and B16/Ox86 cells grew slightly slower with doubling times of 16.5 and 18 hours, respectively, possibly due to the need to culture the cells in both G418 and zeocin. In agreement with our previous results (9), subcutaneous B16/3L tumor growth was delayed as compared with B16 tumors in C57BL/6 mice ( Fig. 2A ; Table 1 ), indicating that ligation of CD3 can induce lymphocyte antitumor activity. Coexpression of CD3L and CD86 on B16 cells (B16/3L86 cells) greatly enhanced tumor suppression and significantly enhanced the survival of tumor challenged mice, with two of six mice remaining tumor-free through 60 days of observation ( Fig. 2A) . Suppression of tumor growth depended on ligation of CD3 because B16 cells expressing the membrane-tethered control antibody (B16/Ox and B16/Ox86) formed tumors that progressed rapidly in C57BL/6 mice at rates that were similar to B16 tumors. Importantly, mice that rejected B16/3L86 tumors developed systemic antitumor memory as shown by protection of 100% of mice from a subsequent challenge with unmodified B16 tumor cells (Fig. 2B) . Expression of CD3L and CD86 on B16 cells also remarkably extended the life span of i.p. tumor-grafted mice (Fig. 2C) . The peritoneum of B16 cellinjected mice was filled with large clusters of tumors, whereas only a few small tumor nodules (<0.2 mm in diameter) were observed in the peritoneum 8 days after inoculation of B16/ 3L86 cells (data not shown). Expression of CD3L and CD86 on B16 cells also completely suppressed the formation of lung tumor colonies in an experimental metastasis model (Fig. 2D) . These results clearly show that membrane-tethered CD3L and CD86 can strongly suppress the growth of poorly immunogenic B16 melanomas in subcutaneous, peritoneal, and metastatic tumor models. CD4 + and CD8 + T cells are not required for the rejection of B16/3L86 tumors. B16/3L cells triggered modest in vitro proliferation of naBve CD4 + and CD8 + T cells, but as expected, coexpression of CD86 with CD3L on B16 cells greatly enhanced T-cell proliferation (B16/3L86 cells in Fig. 3A) . To determine if expression of CD3L and CD86 on B16 cells could induce CTL activity to these poorly immunogenic melanoma cells, naBve CD4 + and CD8 + T cells were cultured with B16 or B16/3L86 cells at defined ratios for 3 days. B16/3L86 cells, but not B16 cells, induced strong CD8 + T-cell -mediated cytotoxicity (Fig. 3B) . By contrast, no significant killing was observed when CD4 + T cells were incubated with either B16 or B16/3L86 cells (Fig. 3B) .
The fact that naBve CD8 + T cells can be directly induced to kill B16/3L86 tumor cells suggested that CD8 + T cells may play an important role in mediating in vivo antitumor activity against B16/3L86 tumors. However, repression of B16/3L86 tumors was equally effective in C57BL/6 mice or in transgenic mice lacking CD8 + T cells (Fig. 3C) . Likewise, depletion of CD4 + T cells in CD8 -/-mice did not hinder suppression of B16/3L86 tumor growth, indicating that neither CD8 + nor CD4 + T cells were necessary for control of B16/3L86 tumor growth (Fig. 3C) . To verify these results, we used specific antibodies to deplete CD4 + and CD8 + T cells in C57BL6 mice. In agreement with the results in CD8 -/-mice, B16/3L86 tumor growth was still suppressed after antibody-mediated depletion of CD4 + or CD8 + T cells (Fig. 3D) . These results clearly show that CD8 + and CD4 + T cells are dispensable for primary rejection of B16/3L86 tumors.
Role of NKT cells in suppression of B16/3L86 tumors. Besides conventional T cells, NKT cells also express CD3 (31) . To investigate if NKT cells play a role in the antitumor activity displayed by CD3L, groups of C57BL/6 mice were injected with an antibody against NK1.1 before s.c. injection of B16 or B16/ 3L86 melanoma cells. This antibody can deplete NKT and NK cells (32) . All mice depleted of NK1.1 + cells developed B16/ 3L86 tumors and displayed significantly reduced survival times as compared with mice treated with a control antibody (Fig. 4A) . Because the NK1.1 marker is expressed on both NK and NKT cells and antibody depletion of immune cells may be incomplete, we also inoculated CD1d -/-mice, which lack classic NKT cells, with B16 or B16/3L86 cells. The survival times of C57BL/6 and CD1d -/-mice bearing B16 tumors were similar, whereas the survival of CD1d -/-mice bearing B16/3L86 tumors was significantly reduced as compared with C57BL/6 mice (Fig. 4B) . These results show a critical role for NKT cells in controlling the growth of B16/3L86 tumors. None of the B16 transfectants expressed the class I -like molecule CD1d, which can present glycosphingolipids to NKT cells ( Supplementary  Fig. S2 ). The B16 transfectants also did not express the NKG2D ligand H60, MULT-1, or Rae-1 ( Supplementary Fig. S2 ), consistent with NKT cell activation by CD3L and CD86 on the B16/3L86 cells. IFN-g is a key mediator of NKT cells (33) . Consistent with a role of NKT cells in controlling tumor growth, B16/3L86 cells rapidly progressed in IFN-gdeficient mice, showing that IFN-g was indispensable for suppression of B16/3L86 tumors (Fig. 4C) . In agreement with a previous report (34) , B16 cells and transfectants were directly sensitive to IFN-g in vitro, resulting in profound growth delay ( Supplementary Fig. S3 ). All the cells displayed similar sensitivity to IFN-g.
Depletion of Tregs improves tumor suppression by unmasking the antitumor activity of CD8 + T cells. B16/3L86 tumor cells effectively activated CD8
+ T cells in vitro (Fig. 3A and B) and (29) . Low doses of cyclophosphamide, an antineoplastic alkylating agent, can decrease the number and/or function of Tregs (25, 35) . To assess whether CD8 + T-cell function could be restored by systemic depletion of Tregs, groups of C57/BL6 mice were i.p. injected with PBS or low-dose cyclophosphamide (2 mg/mouse) 1 day before they were s.c. transplanted with B16 or B16/3L86 cells. This dose of cyclophosphamide has previously been shown to selectively deplete Tregs (23, 35) . All mice pretreated with low-dose cyclophosphamide completely rejected B16/3L86 tumors (Fig. 5A) . By contrast, cyclophosphamide did not affect the growth of B16 tumors. Periodic administration of low-dose cyclophosphamide enhanced B16/3L86 tumor rejection but was not more effective than a single injection given 1 day before tumor inoculation; four of five mice that received cyclophosphamide treatment on days -1 and 20 remained tumor-free after injection of B16/3L86 tumor cells, and 100% of mice repetitively treated with low-dose cyclophosphamide on days -1, 20, and 40 remained tumor-free (data not shown). Subsequent experiments therefore used a single i.p. injection of 2 mg cyclophosphamide on day -1. To confirm these results, Tregs were depleted by i.p. injection of an anti-CD25 antibody on day -4. The dose and timing we used were previously shown to selectively deplete/inhibit Tregs (24) . In agreement with lowdose cyclophosphamide treatment, 100% of mice treated with anti-CD25 antibody remained tumor-free after injection of B16/3L86 cells (Fig. 5B) . These results show that depletion of Tregs greatly enhanced rejection of B16 tumor cells expressing CD3L and CD86. To determine the mechanism by which depletion of Tregs enhanced antitumor immunity, CD8 -/-mice were treated with low-dose cyclophosphamide before challenge with B16/3L86 cells. In contrast to wt C57BL/6 mice, B16/3L86 tumors eventually progressed in CD8 -/-mice after low-dose cyclophosphamide treatment (Supplementary Fig. S4 ), showing that CD8 + T cells were required for the enhanced antitumor activity observed after depletion of Tregs by low-dose cyclophosphamide treatment. To determine if long-term protective immunity against B16 tumors required T cells, mice that rejected B16/3L86 tumors were depleted of CD4 + or CD8 + T cells before rechallenge with wt B16 tumor cells. Mice treated with control antibody completely rejected B16 tumors, whereas mice depleted of CD8 + T cells developed tumors within 11 days + T cells were only partially protected (Fig. 5C) . Thus, the long-term protective immunity generated by B16/3L86 tumors depended on both CD8 + and CD4 + T cells. Low-dose cyclophosphamide increases activated CD8 + T cells in B16/3L86 tumors. TILs play an important role in the management of tumor growth (36) . TILs could not be retrieved from subcutaneous B16/3L86 tumors at early times due to their slow growth. We therefore examined lymphocyte infiltration in B16 peritoneal tumors. Groups of mice were i.p. injected with B16 or B16/3L86 cells and peritoneal lymphocytes were recovered 5 and 8 days later. On day 5, very few lymphocytes could be retrieved from mice injected with B16 cells. On the other hand, abundant lymphocytes were present in B16/3L86 tumors on day 5. On day 8, the numbers of NKT, CD4
+ , and CD8 + T cells were higher in B16/3L86 cell -injected mice as compared with mice bearing B16 i.p. tumors. By contrast, more NK cells accumulated in the peritoneum of B16 tumor -grafted mice (Supplementary Fig. S5 ). All TIL populations declined 11 days after i.p. injection of B16 or B16/3L86 tumor cells (data not shown), possibly due to reduced numbers of B16/3L86 cancer cells or suppression of lymphocyte infiltration in advanced B16 tumors. CD8
+ effector cells and Tregs isolated from peritoneal tumors on day 8 were also analyzed. Effector CD8 + T cells, which produce IFN-g, composed 20% to 30% of the CD8 + T-cell population in B16 and B16/3L86 i.p. tumors. Low-dose cyclophosphamide treatment robustly increased the number of IFN-g + CD8 + T cells and decreased the number of Tregs in B16/3L86 tumors ( Supplementary Fig. S5 ). Thus, the ratio of CD8 + IFN-g + T cells to Tregs in peritoneal B16/3L86 tumors increased significantly after treatment with low-dose cyclophosphamide (Fig. 5D) .
Tumor-located CD3L and CD86 can create a tumor-destructive environment. The ability of tumor cells expressing CD3L and CD86 to activate NKT cells raised the possibility that unmodified neighboring tumor cells could also be suppressed by intratumorally activated lymphocytes. To test this idea, B16 melanoma cells were mixed with equal numbers of B16/3L86 cells, 3T3 cells, or 3T3/3L86 cells before they were s.c. injected in mice. 3T3/3L86 cells are mouse fibroblasts engineered to stably express CD3L and CD86 on their surface. Mice injected with B16 tumor cells alone or with a mixture of B16 and 3T3 cells developed tumors before day 10. By contrast, tumors grew significantly slower in mice inoculated with a mixture of B16 and B16/3L86 cells or B16 and 3T3/3L86 cells (Fig. 6A) . Similarly, s.c. injection of a mixture of 3T3/3L86 cells and TSA breast adenocarcinoma cells resulted in significantly slower tumor growth (Fig. 6B) . Thus, CD3L and CD86 can induce a tumor-destructive environment to kill bystander tumor cells. To further investigate the therapeutic potential of membrane-tethered anti-CD3 antibodies for cancer therapy, we constructed adenoviral vectors expressing CD3L (Ad/3L), membrane-tethered anti-phOx control antibody (Ad/Ox), CD86 (Ad/86), or anti-CD28 scFv (Ad/28L). The membranetethered anti-CD28 antibody was examined to potentially provide costimulation via CD28 ligation without modulating T-cell activity by ligation of CTLA-4. In vitro transfection assays showed that the recombinant adenoviruses expressed the Fig. 4 . NKTcells are essential for the antitumor activity induced by CD3L and CD86. A, groups of seven C57BL/6 mice were s.c. injected with 2 Â 10 6 B16 or B16/3L86 cells on day 0. Mice were also i.p. injected with anti-NK1.1 or control antibody and mouse survival was followed. B, groups of C57BL/6 or CD1d -/-mice (n = 6) were s.c. injected with 2 Â 10 6 B16 or B16/3L86 cells on day 0 and mouse survival was monitored. C, C57BL/6 or IFN-g -/-mice (n = 6) were s.c. transplanted with 1 Â10 6 B16 or B16/3L86 cells on day 0 and tumor growth was followed. Bars, SE.
appropriate transgenes (Supplementary Fig. S6 ). Intratumoral injection of B16 tumors with Ad/3L and Ad/86 produced modest delay in the growth of subcutaneous tumors (Supplementary Fig. S7 ). The modest response of B16 tumors to adenoviral therapy may be related to the poor infectivity of B16 cells by recombinant adenovirus (Supplementary Fig. S8 ). We therefore tested adenoviral therapy of TSA breast adenocarcinoma tumors because TSA cells were more easily infected by adenovirus vectors (Supplementary Fig. S8 ). Intratumoral injection of TSA tumors with combinations of either Ad/3L and Ad/86 or Ad/3L and Ad/28L significantly suppressed tumor growth (Fig. 6C) . One of eight mice experienced complete tumor regression when treated with Ad/3L and Ad/28L.
Discussion
Tumor-located activation of lymphocytes by membranetethered antibodies is under investigation for the therapy of poorly immunogenic tumors (reviewed in ref. 8) . In this study, we expressed a membrane-tethered anti-CD3 antibody (CD3L) on poorly immunogenic melanoma cells to activate CD3 + lymphocytes locally in tumors. CD86 was also expressed on the cancer cells to provide costimulation to more completely activate T cells and promote generation of memory CD8 + T cells (37, 38) . We expected that local activation of tumor-infiltrating T cells via ligation of CD3 would provide strong antitumor activity without the side effects associated with systemic T-cell activation by CD3 ligation (2) . Indeed, expression of CD3L and CD86 on the surface of B16 melanoma cells provided strong antitumor activity and suppressed the growth of subcutaneous, peritoneal, and metastatic tumors. Surprisingly, both CD4 + and CD8 + T cells were totally dispensable for the suppression of primary tumor growth. Rather, we found that tumor suppression was largely mediated by NKT cells. However, chemical or antibody depletion of Treg cells greatly enhanced local T-cell antitumor activity and produced complete rejection of primary tumors. Thus, in combination with Treg depletion, membranetethered anti-CD3 scFv along with CD86 effectively activated both innate and adaptive immune responses to control tumor growth.
Our study is the first to show that NKT cells play a critical role in the antitumor activity induced by dual engagement of CD3 and CD28. B16/3L86 tumors progressed more rapidly after depletion of NK1.1 + cells (Fig. 4A) or when transplanted into CD1d -/-mice (Fig. 4B) , showing a major role for NKT cells in suppression of tumor cells expressing CD3L and CD86. T cells were dispensable for suppression of primary tumor growth because antibody depletion of CD4 + and CD8 + T cells did not dampen antitumor activity against B16/3L86 tumors (Fig. 3D ) and B16/3L86 tumor growth was still significantly delayed in CD8 -/-mice, even when CD4 + T cells were also depleted (Fig. 3C) . Distinct populations of NKT cells exhibit diverse effects on immunoregulation and tumor suppression (39) . Because depletion of CD4 + or CD8 + cells did not affect primary antitumor activity, the effector NKT cells in our study were likely CD1d
. These NKT cells may be similar to liver-derived CD4 -NKT cells that were shown to mediate rejection of MCA and B16F10 tumors in mice (39) . NKT cells can initiate both innate and adaptive immune responses, largely by secreting IFN-g to promote activation of CD8 + T cells and NK cells (40) . IFN-g also directly suppressed the growth of B16 cells and B16 transfectants (Supplementary Fig. S3 ). Our data showing complete loss of B16/3L86 tumor suppression in IFN-g -/-mice indicate a major role for IFN-g secretion by NKT cells in the antitumor activity induced by membrane-tethered anti-CD3 antibodies. CD4 + CD25 + FoxP3 + Tregs accumulate in the spleen, tumors, and draining lymph nodes of mice bearing B16 tumors (29) . Systemic depletion of Tregs with anti-CD25 or low-dose cyclophosphamide treatment can promote rejection of tumors in mice (24 -26) . In our study, depletion of Tregs with either anti-CD25 antibodies or low-dose cyclophosphamide dramatically increased the life span of mice injected with B16/3L86 tumors with up to 100% long-term survivors. Besides CD4 + and CD8 + T cells, Tregs have also been reported to suppress the function of NKT cells (17, 41) . However, the beneficial effects of Treg depletion by low-dose cyclophosphamide were completely lost in CD8 -/-mice ( Supplementary Fig. S4 ), indicating that Tregs mainly suppressed local CD8 + T-cell function rather than NKT cell antitumor activity. Likewise, cyclophosphamide treatment significantly increased the ratio of activated IFNg + CD8 + T cells to CD4 + FoxP3 + T cells in B16/3L86 tumors (Fig. 5D) , indicating that the activity of tumor-infiltrating CD8 + T cells was restored on depletion of Tregs. Interestingly, effective antitumor memory was induced against B16 melanoma cells regardless of whether Tregs were depleted (Figs. 2B and  5C ). Taken together, these results indicate that CD8 + T cells and NKT cells were effectively activated in B16/3L86 tumors (Fig. 6D) . Tregs seemed to suppress local CD8 + T-cell antitumor activity but not their differentiation into memory T cells. Hence, mice were protected from rechallenge with parental B16 melanoma cells, suggesting that activated memory CD8 + T cells could recognize low levels of tumor-associated antigens presented by MHC molecules on B16 cancer cells. In addition, Tregs did not seem to suppress NKT cells, which accounted for most of the antitumor activity against B16/3L86 tumors. Systemic depletion of Tregs unmasked local CD8 + T-cell antitumor activity, which, in concert with NKT cells, entirely eradicated B16/3L86 tumors.
Besides NKT cells and CD8 + T cells, CD3L and CD86 also effectively activated CD4 + T cells (Fig. 3A) , and B16/3L86 cells induced the expansion of CD4 + T cells inside peritoneal tumors (Supplementary Fig. S5 ). CD4 + T cells are critical for generation of CD8 + T-cell -dependent memory responses (42) . The strong memory response observed against parental B16 melanoma cells in mice that rejected B16/3L86 tumors suggests that coactivation of both CD4 + and CD8 + T cells may promote effective T-cell memory responses. Indeed, whereas depletion of CD8 + T cells completed abrogated antitumor memory responses, depletion of CD4 + T cells also hindered antitumor memory (Fig. 5C ). The development of long-term antitumor immunity implies that T cells with specificity for tumor antigens infiltrated B16/3L86 tumors and were activated by CD3 and CD28 ligation. This is consistent with previous studies showing that lymphocytes recovered from human melanomas display specificity for melanoma-associated antigens (43, 44) . Our results indicate that CD3L and CD86 produce sufficient in vivo activation and expansion of melanoma-specific T cells to effectively generate antitumor memory.
Our study revealed that CD3L and CD86 suppressed the growth of tumor cells expressing these molecules and also helped control the growth of neighboring cancer cells. This is important because cancer cells can escape immunosurveillance by down-regulating expression of MHC molecules or tumor antigens, eventually leading to tumor repopulation and treatment failure (45) . Expression of tumor antigens at low levels can also result in partial activation of TILs and poor antitumor activity (46) . Fibroblasts engineered to express CD3L and CD86 induced in vivo bystander killing of neighboring B16 melanoma or TSA breast carcinoma cells, which may help overcome antigen escape mutants. Expression of membranetethered anti-CD3 scFv with CD86 may help harness the immune system for the therapy of otherwise poorly immunogenic tumors.
Preliminary studies in which solid tumors were directly injected with recombinant adenoviruses expressing CD3L and CD86 or membrane-tethered anti-CD28 scFv showed good antitumor activity. We did not observe obvious side effects, suggesting that this approach may be clinically useful. A future challenge is to use delivery vectors such as recombinant viruses, cell delivery systems, or bispecific antibodies to locally ligate CD3 and CD28 on lymphocytes present in tumors.
Expression of membrane-tethered anti-CD3 scFv on tumors mimics anti-CD3 -based bispecific antibodies, which are novel reagents designed to bind both tumor-associated surface antigens and CD3 on T cells. Bispecific antibodies, as well as newer, highly potent reagents such as bispecific T-cell engager molecules, are under clinical development for the treatment of cancer (3 -5, 7, 47) . Our results showing that CD3 + NKT cells can be activated by membrane-tethered CD3 scFv to provide potent antitumor activity implies that NKT cells may also be important for the antitumor activity of bispecific antibodies. Stimulation of NKT cells, for example by systemic administration of stimulatory glycolipids, may be a rational approach to enhance the efficacy of CD3L therapy as well as anti-CD3 bispecific antibody therapy (48, 49) . Our results also suggest that, in common with membrane-tethered anti-CD3, bispecific antibody therapy may also be improved by depleting Tregs.
In summary, we investigated the mechanism of tumorlocated lymphocyte activation by membrane-tethered anti-CD3 antibody and CD86. We found that NKT cells play an important role in mediating primary tumor rejection in the presence of Tregs, whereas both NKT cells and CD8 + T cells provided strong antitumor activity after Tregs were depleted from mice. Importantly, memory antitumor T cells were effectively generated even in the presence of Tregs. Furthermore, expression of anti-CD3 scFv and CD86 on cells induced bystander cytotoxicity to neighboring cancer cells in tumors. Local expression of membrane-tethered CD3 scFv and CD86 created a tumor destruction environment that may lead to clinical approaches for cancer therapy.
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